Gilead and EVOQ Therapeutics Announce Collaboration to Advance Immunotherapies
Gilead Sciences, Inc. (Nasdaq: GILD) and EVOQ Therapeutics, Inc. (EVOQ) today announced a collaboration and licensing agreement to advance EVOQ’s proprietary technology for the treatment of rheumatoid arthritis (RA) and lupus. EVOQ’s NanoDisc technology is designed to enable lymph-targeted delivery of ...
United States Foster City Flavius Martin William Brinkerhoff Exchange Commission Nanodisc Technology To
Source: pharmiweb.com